

WEDNESDAY 16<sup>th</sup> OCTOBER 2013 COMMENCING 09.30 AM  
(UNTIL 4.00 PM APPROX)

AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

### AGENDA

1. Welcome and introduction

Enclosure

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

1/AWMSG/1013

**To protect commercial confidentiality, the first appraisal will be conducted in private.  
The final appraisal recommendation will be announced in public**

5. Appraisal 1 – Full submission (WPAS)

2/AWMSG/1013

**Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil**

**Appendices**

**fumarate (Stribild<sup>®</sup>▼)** for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral-treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild

**The meeting will now open to the public (approx 10.15 am)**

6. Chairman's report (verbal update)

7. Appraisal 2 – Full submission (reappraisal)

3/AWMSG/1013

**Pegvisomant (Somavert<sup>®</sup>)** is indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated

**Appendices**

8. Appraisal 3 – Full submission

4/AWMSG/1013

**Tegafur/gimeracil/oteracil (Teysuno<sup>®</sup>▼)** for the treatment of advanced gastric cancer in adults when given in combination with cisplatin

**Appendices**

- |     |   |  |
|-----|---|--|
| 9.  | <b>Appraisal 4 – Full submission</b><br><b>5-aminolaevulinic acid (Ameluz<sup>®</sup>▼)</b> for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp (Olsen grade 1 to 2)   | <b>5/AWMSG/1013</b><br><b>Appendices</b> |
| 10. | <b>Appraisal 5 – Full submission</b><br><b>Lisdexamfetamine dimesylate (Elvanse<sup>®</sup>▼)</b> as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders | <b>6/AWMSG/1013</b><br><b>Appendices</b> |
| 11. | <b>Appraisal 6 – Limited submission</b><br><b>Raltegravir (Isentress<sup>®</sup>)</b> is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adolescents and children from the age of 2 years   | <b>7/AWMSG/1013</b><br><b>Appendices</b> |
| 12. | <b>Reappraisal following Independent Review</b><br><b>Pazopanib (Votrient<sup>®</sup>)</b> for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy   | <b>8/AWMSG/1013</b><br><b>Appendices</b> |
| 13. | <b>AWPAG update (draft minutes of September 2013 meeting)</b>   | <b>9/AWMSG/1013</b>                      |
| 14. | <b>Primary Care Prescribing Analysis – Gluten Free</b>  | <b>10/AWMSG/1013</b>                     |
| 15. | <b>Tramadol and Morphine</b><br><b>National Prescribing Indicator (NPI) report</b>  | <b>11/AWMSG/1013</b>                     |
| 16. | <b>NPI Quarterly Report</b>   | <b>12/AWMSG/1013</b>                     |
| 17. | <b>Prescribing of Denosumab (Prolia<sup>®</sup>) in Wales (Review)</b>  | <b>13/AWMSG/1013</b>                     |
| 18. | <b>All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation</b>   | <b>14/AWMSG/1013</b>                     |
| 19. | <b>Supply and administration of intranasal fentanyl spray in non-specialist palliative inpatient settings</b>   | <b>15/AWMSG/1013</b>                     |
| 20. | <b>Date of next meeting:</b><br><b>Wednesday 20<sup>th</sup> November in Cardiff</b>  |  |